Long-term outcomes with pembrolizumab in Hodgkin lymphoma, the “incredible ULK” alleviates β-thalassemia, and recommendations for managing CAR T hematotoxicity

Blood Podcast

English - September 07, 2023 16:30 - 19 minutes - 26.6 MB - ★★★★ - 44 ratings
Life Sciences Science hematology oncology medical medical research Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: How I Manage Inpatient Consultations for Quantitative Neutrophil Abnormalities in Adults

Next Episode: Obinutuzumab, ibrutinib, and venetoclax in untreated CLL with deletion(17p)/TP53 mutation; NOTCH2 mutants promote chemo-resistance in DLBCL; and the role of DBY/HLA class II complexes in chronic GVHD

In this week's episode, we’ll learn about long-term outcomes with pembrolizumab in relapsed/refractory classical Hodgkin lymphoma. Next, what’s behind the accumulation of toxic free alpha-globin in beta-thalassemia? Finally, a road map for managing CAR T cell hematologic toxicity.